Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLXN Silexion Therapeutics Corp

Not Yet Opened 01-28 16:00:00 EST

2.04

-0.05

-2.39%

盘后2.00

-0.04-1.96%

19:38 EST

High2.09	Low2.02	Vol14.37K
Open2.09	D1 Closing2.09	Amplitude3.34%
Mkt Cap6.38M	Tradable Cap5.62M	Total Shares3.13M
T/O29.43K	T/O Rate0.52%	Tradable Shares2.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":2.04,"timestamp":1769634000000,"preClose":2.09,"halted":0,"volume":14372,"hourTrading":{"tag":"盘后","latestPrice":2,"preClose":2.04,"latestTime":"19:38 EST","volume":845,"amount":1699.845,"timestamp":1769647084855,"change":-0.04,"changeRate":-0.019608,"amplitude":0.019608},"delay":0,"changeRate":-0.02392344497607647,"floatShares":2753490,"shares":3126642,"eps":-25.2122,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"01-28 16:00:00 EST","open":2.09,"high":2.09,"low":2.0201,"amount":29433.7510844,"amplitude":0.033445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-25.2122,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769677200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.09,"preHourTrading":{"tag":"盘前","latestPrice":2.09,"preClose":2.07,"latestTime":"09:05 EST","volume":423,"amount":870.1543152,"timestamp":1769609101582,"change":0.02,"changeRate":0.009662,"amplitude":0.043527},"postHourTrading":{"tag":"盘后","latestPrice":2,"preClose":2.04,"latestTime":"19:38 EST","volume":845,"amount":1699.845,"timestamp":1769647084855,"change":-0.04,"changeRate":-0.019608,"amplitude":0.019608},"volumeRatio":0.446777},"requestUrl":"/m/hq/s/SLXN/tweets","defaultTab":"tweets","newsList":[{"id":"2605107703","title":"Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107703?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002230,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on oncology, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29, 2026, in Boston, MA. Company management, including CEO Ilan Hadar, will participate in the event, and Silexion will also be an official partner of the summit. Silexion is developing SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes, with plans to initiate a Phase 2/3 clinical study in locally advanced pancreatic cancer in mid-2026. Interested parties can arrange one-on-one meetings with Silexion management through the company’s investor relations representatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL7ykQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2601890363","title":"Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890363?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:25","pubTimestamp":1767705917,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has published a shareholder letter from Chairman and Chief Executive Officer Ilan Hadar. The letter highlights achievements in 2025, including positive preclinical data for SIL204, completion of regulatory toxicology studies, and positive feedback from Germany’s Federal Institute for Drugs and Medical Devices regarding Phase 2/3 trial design. The letter also outlines plans to initiate a Phase 2/3 clinical trial in locally advanced pancreatic cancer in the first half of 2026 and discusses expected milestones for the upcoming year. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5TLjpW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2601560892","title":"Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601560892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601560892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:30","pubTimestamp":1767702609,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced significant preclinical research results for its lead RNA interference  therapy, SIL204, targeting KRAS-driven cancers. The company reported that SIL204 demonstrated substantial tumor inhibition in human KRAS-mutated cancer cell line models, including pancreatic, colorectal, and lung cancers. These findings, achieved in 2025, have not yet been presented in human clinical trials, which are scheduled to begin in the first half of 2026. Silexion also completed regulatory toxicology studies and received positive feedback from Germany's Federal Institute for Drugs and Medical Devices  on its Phase 2/3 trial design, paving the way for the upcoming clinical trial of SIL204 in locally advanced pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3cF3Gk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SLXN","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","SG9999014039.USD","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2591998763","title":"Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2591998763","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591998763?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:40","pubTimestamp":1765892410,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced the submission of its regulatory application in Israel to initiate a Phase 2/3 clinical trial of SIL204 for patients with locally advanced pancreatic cancer. This regulatory submission follows positive feedback from the German Federal Institute for Drugs and Medical Devices  and successful toxicology studies demonstrating no systemic organ toxicity. Silexion plans to file additional regulatory applications in Germany and the European Union in the first quarter of 2026, with expansion to U.S. clinical sites anticipated after the safety run-in is completed in Israel and Germany. The Israeli portion of the trial will be conducted in collaboration with Sheba Medical Center, pending regulatory and ethics approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6vPlbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","SLXN","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2591665647","title":"Silexion Therapeutics Initiated at Buy by Litchfield Hills","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591665647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:55","pubTimestamp":1765810500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 09:55 ET (14:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2588056944","title":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056944","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056944?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683748,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS RECEIVES P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2588053763","title":"Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053763?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2588053083","title":"Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053083?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2588537080","title":"Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588537080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588537080?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680400,"startTime":"0","endTime":"0","summary":"Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the en","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197820/0/en/Silexion-Therapeutics-Receives-Positive-Feedback-from-German-Health-Authority-on-Design-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","SLXN","BK4539","BK4139"],"gpt_icon":0},{"id":"2588298081","title":"Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588298081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588298081?lang=en_us&edition=fundamental","pubTime":"2025-12-02 13:50","pubTimestamp":1764654605,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has released a corporate presentation detailing its progress in developing RNA silencing treatments targeting mutated KRAS proteins, which are key drivers in several aggressive cancers, including pancreatic, colorectal, lung, small bowel, and appendix cancers. The company's first-generation product, Loder, demonstrated a survival benefit in clinical studies for patients with mutant KRAS-driven locally advanced pancreatic cancer. In these studies, patients receiving Loder in combination with standard-of-care chemotherapy showed a median overall survival of 22.7 months compared to 13.4 months for those on chemotherapy alone. Silexion's second-generation siRNA candidate, SIL204, is designed to enhance cellular delivery, improve stability, and offer broader antitumor activity. The platform supports both intratumor and systemic administration, aiming to treat both primary tumors and metastases. Preclinical results with SIL204 indicate potential applicability for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL8XhCx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2586899470","title":"BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2586899470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586899470?lang=en_us&edition=fundamental","pubTime":"2025-11-26 00:46","pubTimestamp":1764089197,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026Nov 25 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA2RTPS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2586471301","title":"Silexion Therapeutics completes toxicology studies for SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471301?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:20","pubTimestamp":1764080440,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the successful completion of toxicology studies for SIL204, the Company’s next-generation RNA silencing ther...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","RNA","BK4588","BK4539","BK4505","IE0009354923.USD","LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2586479668","title":"Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479668","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479668?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:15","pubTimestamp":1764080100,"startTime":"0","endTime":"0","summary":"Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194426/0/en/Silexion-Therapeutics-Successfully-Completes-Toxicology-Studies-for-SIL204-Next-Generation-RNA-Silencing-Therapy-Ahead-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4505","BK4539","SLXN","RNA","BK4585","BK4588","IE0009354923.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2583507226","title":"Maxim Group Remains a Buy on Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583507226?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:15","pubTimestamp":1763133336,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics yesterday and set a price target of $12.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2583887591","title":"Silexion Therapeutics Corp : Maxim Group Cuts Target Price to $12 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2583887591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583887591?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:54","pubTimestamp":1763045663,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2582372172","title":"Silexion Therapeutics reports third quarter net loss of $7.5 million and cash balance of $9.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372172","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372172?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:07","pubTimestamp":1762956470,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. reported a net loss of $7.5 million, or  per share, for the nine months ended September 30, 2025, compared to a net loss of $14.8 million, or  per share, for the same period in 2024, reflecting a 49.3% decrease. Cash and cash equivalents increased to $9.2 million as of September 30, 2025, from $1.2 million at December 31, 2024. Shareholders' equity improved to $7.0 million from a capital deficiency of $4.0 million at the end of 2024. The company completed a public offering and received proceeds from warrant exercises totaling approximately $9.5 million during the third quarter. Silexion regained full compliance with Nasdaq listing requirements in September 2025. Business developments included new preclinical data for SIL204 and preparations for Phase 2/3 clinical trial initiation in the first half of 2026, with ongoing regulatory submissions in Israel and the EU.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2DTyQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2578506665","title":"Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578506665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578506665?lang=en_us&edition=fundamental","pubTime":"2025-10-25 23:55","pubTimestamp":1761407713,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics, with a price target of $24.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN"],"gpt_icon":0},{"id":"2571328485","title":"Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328485","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328485?lang=en_us&edition=fundamental","pubTime":"2025-09-30 21:06","pubTimestamp":1759237595,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL8725M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2571328352","title":"BUZZ-Silexion Therapeutics climbs on promising cancer drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328352","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328352?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:59","pubTimestamp":1759237185,"startTime":"0","endTime":"0","summary":"BUZZ-Silexion Therapeutics climbs on promising cancer drug data** Shares of drug developer Silexion Therapeutics SLXN.O rise 11% to $3.75 premarket** Says its experimental cancer drug, SIL204, showed strong activity in lab tests, targeting a wide range of KRAS mutations linked to aggressive cancers** Reports inhibition rates between 83.5% and 99.7% in 11 human cancer cell lines, including its first data in gastric cancer and expanded results in colorectal cancer** SIL204 also showed high potency against the G12R mutation, which affects about 17% of pancreatic cancer patients** Plans to start mid-to-late stage trials in the first half of 2026** As of last close, stock down 88% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH0YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2571347020","title":"Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-Kras Activity of Sil204, Demonstrating up to 99.7% Inhibition and First Evidence in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2571347020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571347020?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUA9KSJDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.0332},{"period":"1month","weight":-0.0188},{"period":"3month","weight":-0.3818},{"period":"6month","weight":-0.7802},{"period":"1year","weight":-0.8993},{"period":"ytd","weight":0.0625}],"compareEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":0.011},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1185},{"period":"1year","weight":0.1504},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.00554},{"month":2,"riseRate":0.75,"avgChangeRate":-0.104682},{"month":3,"riseRate":1,"avgChangeRate":0.013692},{"month":4,"riseRate":0.75,"avgChangeRate":-0.019534},{"month":5,"riseRate":0.4,"avgChangeRate":0.010327},{"month":6,"riseRate":0.4,"avgChangeRate":-0.035519},{"month":7,"riseRate":1,"avgChangeRate":0.055675},{"month":8,"riseRate":0.4,"avgChangeRate":-0.277749},{"month":9,"riseRate":0.6,"avgChangeRate":-0.230878},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction